ES2268394T3 - Inhibidores de piranona y pirandiona de la arn polimerasa dependiente del arn del virus de la hepatitis c. - Google Patents

Inhibidores de piranona y pirandiona de la arn polimerasa dependiente del arn del virus de la hepatitis c. Download PDF

Info

Publication number
ES2268394T3
ES2268394T3 ES03745205T ES03745205T ES2268394T3 ES 2268394 T3 ES2268394 T3 ES 2268394T3 ES 03745205 T ES03745205 T ES 03745205T ES 03745205 T ES03745205 T ES 03745205T ES 2268394 T3 ES2268394 T3 ES 2268394T3
Authority
ES
Spain
Prior art keywords
nhc
group
compound
salt
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03745205T
Other languages
English (en)
Spanish (es)
Inventor
Allen J. Agouron Pharmaceuticals Inc. Borchardt
Michael Paul Agouron Pharmaceuticals Inc. Goble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2268394T3 publication Critical patent/ES2268394T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
ES03745205T 2002-04-01 2003-03-21 Inhibidores de piranona y pirandiona de la arn polimerasa dependiente del arn del virus de la hepatitis c. Expired - Lifetime ES2268394T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36938102P 2002-04-01 2002-04-01
US369381P 2002-04-01

Publications (1)

Publication Number Publication Date
ES2268394T3 true ES2268394T3 (es) 2007-03-16

Family

ID=28675577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03745205T Expired - Lifetime ES2268394T3 (es) 2002-04-01 2003-03-21 Inhibidores de piranona y pirandiona de la arn polimerasa dependiente del arn del virus de la hepatitis c.

Country Status (11)

Country Link
US (1) US6878727B2 (https=)
EP (1) EP1490350B1 (https=)
JP (1) JP2005526102A (https=)
AT (1) ATE337309T1 (https=)
AU (1) AU2003215826A1 (https=)
BR (1) BR0308856A (https=)
CA (1) CA2480583C (https=)
DE (1) DE60307804T2 (https=)
ES (1) ES2268394T3 (https=)
MX (1) MXPA04009672A (https=)
WO (1) WO2003082848A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
HRP20130971T1 (hr) 2004-02-20 2013-11-08 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
JP4663733B2 (ja) * 2004-10-29 2011-04-06 シェーリング コーポレイション 抗ウイルス物質としての置換5−オキソピラゾールおよび置換[1,2,4]トリアゾール
WO2006127289A1 (en) * 2005-05-20 2006-11-30 Valeant Research & Development Treatment of hcv with subtherapeutic doses of ribavirin
US7816348B2 (en) * 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP5244604B2 (ja) * 2006-10-13 2013-07-24 あすか製薬株式会社 ベンゾチアゾール化合物の製造方法
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
US8242140B2 (en) * 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2010535155A (ja) * 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
WO1995003056A1 (en) 1993-07-19 1995-02-02 Tokyo Tanabe Company Limited Hepatitis c virus proliferation inhibitor
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU777040B2 (en) * 1999-02-22 2004-09-30 Shire Biochem Inc. (1,8) naphthyridine derivatives having antiviral activity
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento

Also Published As

Publication number Publication date
MXPA04009672A (es) 2004-11-12
DE60307804T2 (de) 2007-01-18
EP1490350A1 (en) 2004-12-29
ATE337309T1 (de) 2006-09-15
CA2480583A1 (en) 2003-10-09
US6878727B2 (en) 2005-04-12
JP2005526102A (ja) 2005-09-02
AU2003215826A1 (en) 2003-10-13
BR0308856A (pt) 2005-02-22
CA2480583C (en) 2008-07-15
US20030195239A1 (en) 2003-10-16
EP1490350B1 (en) 2006-08-23
WO2003082848A1 (en) 2003-10-09
DE60307804D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
TW201930315A (zh) 具抗b型肝炎病毒(hbv)活性之新穎高活性胺基-噻唑取代之吲哚-2-甲醯胺
AU2019370734A1 (en) 6,7-dihydro-4H-pyrazolo(1,5-a)pyrazine indole-2-carboxamides active against the hepatitis B virus (HBV)
ES2268394T3 (es) Inhibidores de piranona y pirandiona de la arn polimerasa dependiente del arn del virus de la hepatitis c.
CA3118387A1 (en) Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
WO2020089453A1 (en) Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
TW202031660A (zh) 具抗b型肝炎病毒(hbv)活性之6,7-二氫-4h-吡唑并[1,5-a]吡脲
TW202031655A (zh) 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-吡唑并[4,3-c]吡啶脲活性劑
TW202031666A (zh) 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-噻唑并[5,4-c]吡啶脲活性劑
CA3138380A1 (en) Novel oxalyl piperazines active against the hepatitis b virus (hbv)
WO2017076187A1 (zh) 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用
JP2024519979A (ja) 抗ウイルス剤としての新規アザインドール誘導体